COMMUNIQUÉS West-GlobeNewswire

EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS)
12/11/2018
WATERTOWN, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today [...]
Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week
12/11/2018
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week Preclinical Data on New Mechanism Antibiotic SMT- [...]
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial
12/11/2018
Focus will be on Milestones for Development and Commercialization CAP-1002 Therapy for Duchenne Muscular Dystrophy LOS ANGELES, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) announced today that [...]
Ziopharm Oncology Announces Immuno-oncology Clinical Supply Agreement with Regeneron to Evaluate Combination Therapy for Patients with Brain Cancer
12/11/2018
BOSTON, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. , (Nasdaq:ZIOP) today announced a clinical supply agreement with Regeneron Pharmaceuticals, Inc. to evaluate Ziopharm’s Ad-RTS-hIL-12 plus veledimex in [...]
Bioxytran Inc’s New Compound for Treating Strokes Will be the Company’s New Health Mission Moving Forward
12/11/2018
Company Formerly Known as U.S. Rare Earth Minerals, Inc. Focusing on First-In-Class Ischemic Stroke Treatment BOSTON, Nov. 12, 2018 (GLOBE NEWSWIRE) -- U.S. Rare Earth Minerals, Inc. today announced that it has changed [...]
Retrophin Announces U.S. FDA Acceptance of NDA Filing for the New Formulation of Thiola® (tiopronin) in the Treatment of Cystinuria
12/11/2018
PDUFA date set for June 30, 2019 SAN DIEGO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug [...]
Kamada Reports Financial Results for Third Quarter and First Nine Months of 2018
12/11/2018
Total Revenues for First Nine Months of 2018 were $66.3 Million, a 1% Decrease Year-Over-Year Gross Profit for First Nine Months of 2018 was $20.2 million, a 1% Decrease Year-Over-Year Adjusted EBITDA was $7.4 Million [...]
Amicus Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference
12/11/2018
CRANBURY, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the Credit Suisse [...]
Matinas BioPharma Reports Third Quarter 2018 Financial Results and Provides Corporate Update
12/11/2018
– Key focus on advancing the development of MAT9001, a proprietary, potential best-in-class cardiovascular therapy in what is projected to be a new, multi-billion dollar prescription-only omega-3 drug class – – Company [...]
Mersana Scientists Present Updates on XMT-1522, XMT-1536 and the Dolaflexin Platform at World ADC 2018
12/11/2018
Mersana Chief Scientific Officer, Timothy B. Lowinger, Ph.D. to chair 2018 Conference CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical [...]
ContraFect Appoints Michael Messinger as Chief Financial Officer
12/11/2018
YONKERS, N.Y., Nov. 12, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX) , a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life- [...]
Oncolytics Biotech® Reports 2018 Third Quarter Financial Results and Provides Corporate Update
12/11/2018
- Checkpoint combination studies support progression into registration pathway for metastatic breast cancer and potential expansion of indications - - Management to host webcast and conference call today at 8:30 a.m. ET [...]
Ziopharm Oncology Announces $50 Million Private Placement
12/11/2018
BOSTON, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that it has entered into definitive securities purchase agreements for the sale of its common stock and warrants to [...]
MatriSys Bioscience appoints Magda Marquet, PhD to the Board of Directors
12/11/2018
SAN DIEGO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- MatriSys B ioscience, Inc ., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, is pleased to announce the appointment of Dr. Magda [...]
AC Immune to Present at the Jefferies 2018 London Healthcare Conference
12/11/2018
Lausanne, Switzerland, November 12, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will [...]
Rule 2.9 Announcement
12/11/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 12 November 2018 [...]
Appointment of Joint Broker
12/11/2018
Summit Therapeutics plc (‘Summit’ or the ’Company’) Appointment of Joint Broker Oxford, UK, and Cambridge, MA, US, 12 November 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism [...]
Publication of Scheme Document
12/11/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR [...]
Innate Pharma presented translational data from the Phase II of monalizumab and cetuximab at SITC
12/11/2018
SITC 2018: FURTHER ANALYSES OF THE PHASE II STUDY OF THE COMBINATION OF MONALIZUMAB AND CETUXIMAB IN HEAD AND NECK PATIENTS SHOW ENCOURAGING SURVIVAL DATA IN BOTH SUBGROUPS OF IO-NAÏVE AND IO-PRETREATED SCCHN PATIENTS [...]

Pages